Ingalls & Snyder’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
Other funds holding IOVA
Ingalls & Snyder's IOVA Position: Q3 2026 in Review
Ingalls & Snyder held its Iovance Biotherapeutics (IOVA) position steady in Q3 2026 at 15,000 shares worth $222K. The position accounts for 0.01% of the portfolio, ranked #415.
Ingalls & Snyder first reported a position in IOVA in Q2 2026 and has held it in 2 quarters since. 335 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.
- Ingalls & Snyder held 15,000 shares of Iovance Biotherapeutics worth $222K as of Q3 2026.
- Ingalls & Snyder left its Iovance Biotherapeutics share count unchanged in Q3 2026.
- Iovance Biotherapeutics made up 0.01% of Ingalls & Snyder's portfolio in Q3 2026, its #415 holding.
- Ingalls & Snyder first reported a position in Iovance Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
- 335 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.
Based on Ingalls & Snyder's 13F filing for Q3 2026, filed 12 Nov 2026.